Figure 5.
Figure 5. Risk/benefit profile of low-dose aspirin (100 mg daily) in 518 polycythemia vera patients enrolled in the ECLAP trial.

Risk/benefit profile of low-dose aspirin (100 mg daily) in 518 polycythemia vera patients enrolled in the ECLAP trial.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal